Pharma Journalist

2nd Gene Therapy for Muscular Disorders Summit
2022-04-04 - 2022-04-07 | Hanson Wade, Hyatt Regency Boston Downtown, 1 Ave de Lafayette, MA, 02111, United States
Mitigating Toxicity & Revolutionizing Muscle Targeting
The 2nd Gene Therapy for Muscular Disorders Summit will be returning as an in-person event to Boston in April 2022, to help gene therapy developers targeting muscular disorders to overcome safety and toxicity
challenges and effectively translate their programs into the clinic.
Highlighting AAV and gene editing challenges for Duchenne’s (DMD), Limb-Girdle (LGMD), Pompe Disease, X-Linked Myotubular Myopathy and other muscular disorders, this industry-focused 4-day event will cover:

Overcoming immunogenicity challenges and mitigate toxicity with high doses
Optimizing vector and promoter choice and design for more efficient delivery tomuscle targets
Defining clinically meaningful muscular endpoints to successfully develop and safely deliver the optimal dose to their muscular targets

Join over 150 fellow industry experts to learn, share and benchmark yourselves against your competitors, and overcome the toxicity and dosage challenges hindering the progress of your gene therapy targeting the muscle.
To know more visit: https://ter.li/tbbaua

7th Innate Killer Summit 2022
2022-03-30 - 2022-04-01 | Sheraton San Diego Hotel & Marina, 1380 Harbor Island Drive, San Diego, CA, 92101, United States
2021 was a game-changing year for the NK cell community. Positive clinical results have forced the field to wake up to the potential of these pioneering approaches.
Supporting the field since its’ infancy, the Innate Killer Summit returns for its 7th year as the leading, industry-defining forum dedicated to advancing the field to achieve clinical success.
Spanning the current drug development landscape, from improving gene editing transduction in discovery to cryopreservation and CMC in scaled manufacturing, this is the definitive meeting to focus on the clinical and scaled phase development of innate cell therapies.
Get your copy of the 2022 agenda here.
Join over 200 experts to characterize and contrast cell sources, supercharge combinations, optimize CMC workflows, examine expansion protocols for high-quality products at scale, and move the field towards persistent, scalable, and cost-effective innate immune cell therapies.
Promising unpublished data, interactive discussion, and engaging networking opportunities join this exclusive summit to forge new collaborations and capitalize on the clinical potential of innate immune cell therapies.

Next Generation Kinase Inhibitors Summit
2022-03-29 - 2022-03-31 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
Celebrating 20 years of FDA approval and high efficacy profiles, kinase inhibitors have changed the face of oncology treatment. However, increasing resistance and safety issues limit the success of existing kinase inhibitor classes.
The inaugural Next Generation Kinase Inhibitors Summit is the only industry-focused meeting dedicated to applying novel kinase biology to drug development and innovating existing programs to produce the next wave of kinase inhibitor drugs which are able to show efficacious and durable clinical response in oncology and beyond.
Boasting 20+ speakers, 1 deep-dive workshop and over 3 days of unrivalled content spanning discovery, R&D and clinical development, this event is a unique opportunity for your team to identify and target the undruggable, elevate drug design for improved target selectivity, overcome the blood brain barrier and rationalize combinations for more durable responses.
Collaborate with 80+ senior drug developers in March to achieve the next generation of these kinase inhibitor therapies with optimized specificity, maximal durability to deliver the best clinical outcomes.
To know more visit: https://kinase-inhibitors-summit.com/

12th World ADC London
2022-03-29 - 2022-04-01 | Novotel London West, 1 Shortlands, Hammersmith, London, W6 8DR, United Kingdom
12th Annual World ADC London
29th March – 1st April 2022
London
The ADC field is going from strength to strength, further catalysed in 2021 by the approvals of Zynlonta and Tivdak respectively, bringing the total number of commercially available ADCs to 11.
Returning in-person in from 29th March – 1st April, be part of the 12th Annual World ADC London and reconnect with 400+ of your peers at the forefront of ADC drug development.
After in-depth research with key opinion leaders within the ADC field, this is your most extensive programme to-date addressing the most pressing challenges facing ADC developers from discovery through to late phase manufacturing.
Take a look at the brand-new agenda here!
The four-streamed, four-day unrivalled programme with 75+ industry-leading speakers will equip you with the insights and connections to nourish your current pipelines of ADCs, discover the next generation of non-traditional ADCs, and confidently define your manufacturing processes.
Register now and join the likes of the likes of Daiichi Sankyo, AstraZeneca, ADC Therapeutics, Seagen and many more to work collaboratively to overcome the distinct challenges ADC drug development holds and maximise the therapeutic window of ADCs.

3rd Annual Gene Therapy for Blood Disorders
2022-03-29 - 2022-03-31 | Boston Logan Airport Hotel, One Hotel Dr, Boston, MA, 02128, United States
In the context of intense scrutiny over the safety and durability of blood disease-targeted gene therapies and a flurry of excitement around novel gene editing technologies, the 3rd Gene Therapy for Blood Disorders Summit will unite the leading large pharma and innovative biotechs to share essential learnings from across this rapidly evolving field, enabling you to progress your pipeline to address the significant unmet need in this field.
Focused specifically on hemophilia, beta-thallasemia and sickle cell-directed gene therapies and gene editing approaches, this event is an invaluable opportunity to learn the realities of durability challenges, understand strategies to guarantee safety at every stage of development and get a head-start in understanding the most promising technologies set to revolutionise the field.
Incorporating insights from translational, clinical and commercial industry experts, as well as leading clinicians actively involved in late-stage trials, this is your opportunity to investigate the realities of managing immunogenicity for systemically administered gene therapies, establishing less cytotoxic conditioning regimens for ex vivo approaches and prepare for the commercial reality of launching a gene therapy and ensuring there is widespread patient adoption.
To know more visit: https://ter.li/u41qa2

STING & TLR-Targeting Therapies
2022-03-22 - 2022-03-24 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The 3rd STING & TLR-Targeting Therapies Summit is coming at a timely inflection point in this field.
With multiple TLR agonists moving into the clinic, STING agonists exposing new challenges, multiple approvals on the horizon, and more novel targets & combinations currently undergoing exciting pre-clinical validation than ever before, this unique and highly anticipated industry-focused meeting will unite experts in innate immunity to overcome the barriers it faces and accelerate clinical breakthrough.
Returning in-person to the biopharma hub of Boston, 30+ expert speakers will take you through case-study led presentations, juicy panel discussions and live Q&A’s, all tailored to suit your TLR, STING & other PRR targeting needs.
Gain connections and insights to plan how to optimize the development of your innate immune agonists into the clinic and overcome obstacles that may impede the delivery of more selective, better-tolerated medicines to improve survival rates in difficult-to-treat cancers.
To know more visit: https://ter.li/z3s9wq

GPCRs - Targeted Drug Discovery Summit
2022-03-22 - 2022-03-24 | DoubleTree Suites Boston-Cambridge, 400 Soldiers Field Rd, Boston, MA, 02134, United States
The inaugural GPCRs – Targeted Drug Discovery Summit has been established to tap into new drug discovery opportunities in undrugged and orphaned GPCRs by better understanding the complex signaling GPCR pathway, leveraging new structural and genetic data as well as, emerging screening tools and technologies and up and coming modalities.
Discover data driven case studies that showcase the challenges, learnings and takeaways currently being faced by large pharma, biotech and academia who are innovating their discovery and development approaches to drug a wider spectrum of clinically relevant but poorly characterized or undrugged GPCRs across a broad range of therapeutic areas such as oncology, age-related diseases and beyond.
Whether you are looking to harness the power of structural biology tools or emerging technologies, join fellow directors, heads and VPs of drug discovery, structural biology, and pharmacology at the GPCRs – Targeted Drug Discovery Summit – the most comprehensive and dedicated scientific and networking forum for innovative biopharma and research institutes to seize the therapeutic opportunities of GPCRs.
To know more visit: https://ter.li/d9fxmw

SMi Presents the 16th Annual Conference: Parallel Trade 2022
2022-03-21 - 2022-03-22 | Virtual Conference: Online Access Only
SMi’s 16th Annual Conference
Parallel Trade
21-22 March, 2022 | Conference
http://parallel-trade.com/pharmajournalistwl
NAVIGATING THE CHALLENGES AND LEGAL LANDSCAPES OF PARALLEL TRADE
SMi presents its 16th annual Parallel Trade conference on the 21st and the 22nd March 2022. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.
The 2022 event will be more significant than ever before due to the transition period follow Brexit now also coming to an end. As such, the UK will no longer be part of the EU free market. This will mean increased medicines prices, reduced access to some specialist drugs and greater risk of supply chain shortages. In a post-Brexit environment, exhaustion of rights will cease to apply to the UK, making import and export a costly business and in a worst-case scenario could effectively kill parallel distribution.
This conference will bring together industry experts to discuss the challenges and drivers of the industry, including the EU regulatory landscape and the impact of the Brexit and the Pandemic together. The conference will also provide global insights on Parallel trade and will reflect on key takeaways for other member states.
Benefits of Attending:

Discover the impact of Covid-19 on Parallel trade as countries begin to release restrictions. How has the sector been influenced?
Engage in discussions on the growth within parallel trade over the past year at the only Parallel Trade specific conference within the EU.
Discuss the impact on UK parallel trade following Brexit, through the eyes of regulators, the pharmaceutical industry and academics
Develop further understanding of the rules and regulation changes over the past 12 months, Parallel Trade, where are we now?

Who Should Attend:
Vice President/ Heads of/General Managers:
• International Trade and Relations
• Supply Chain Development – Brexit
• Brexit Implementation
• Market Access
• Supply Chain Manager
• Parallel trade reporting
• Regulatory Affairs
• IP
• Purchasing
• Policy Patent Operations
• European Affairs
• Supply and Demand
• Attorney
• Distribution
Please visit http://parallel-trade.com/pharmajournalistwl for more information, to download the full agenda, or to register your place. If you would like to speak to someone about the event please contact Alia Malick amalick@smi-online.co.uk or call +44 (0)20 7827 6168.

2nd TPD Europe Summit
2022-03-15 - 2022-03-17 | London, UK
2021 marked a successful year for the protein degradation field with several candidates entering the clinic. As the European centric targeted protein degradation landscape matures and the number of pre-clinical candidates expected to enter clinical development in the next year grows ever more, the 2nd TPD Europe Summit returns, in person, to highlight key challenges and opportunities ahead!
Built with biopharma in mind, join us as we take a deep dive into how European leaders of protein degradation are approaching key translational challenges including optimisation of selectivity, bioavailability and PKPD to ensure the safety, efficacy and potency of their clinical pipelines in 2022 and beyond!
Be at the heart of the discussion by joining 180+ Senior Scientists, Principal Investigators & Heads of Discovery, Pre-Clinical & Translational Development from Europe and around the globe for two dedicated streams of exciting content over three days to capitalise on this emerging therapeutic class.
Key Highlights Not to Miss:

Hear from Kevin Moreau, Assoicate Director PROTAC Safety Science, AstraZeneca as he discusses key PROTAC safety considerations for both oncology and non-oncology indications including how to optimise the safety profile, and what is acceptable for non-oncology targets

Delve into COFFEE (covalent functionalisation followed by E3 electroporation), which tests neo-substrate degradation by chemically modified E3 ligase components. Brought to you by Benika Pinch, Principal Scientist, Novartis, she discusses how to assess the cellular activity of E3 ligase components

Uncover how protein manipulation using peptides can be used to degrade proteins using either the UPS or lysosomal pathways. This exciting approach relocates protein within the cell and modulates their interactions. Hear Max Cynader, CEO & Co-Founder Primary Peptides discuss in detail!

Amine Sadok, Head of Biology at Monte Rosa Therapeutics will be discussing how they have identified a potent and selective NEK7 molecular glue degrader as a novel CRBN neo-substrate

Digital passes available
To know more visit: https://ter.li/j3ytqu

SMi’s 3rd Annual AI in Drug Discovery Conference
2022-03-14 - 2022-03-15 | London, United Kingdom
SMi’s 3rd Annual AI in Drug Discovery Conference
Conference: 14 – 15 March 2022
London, UK
Website: http://www.ai-indrugdiscovery.com/PJwl
Chaired by Darren Green, Director of Computational Chemistry, GSK
Sponsored by: Optibrium
Exploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare
SMi Group is proud to present its 3rd Annual AI in Drug Discovery Conference, taking place on the 14th and 15th March 2022 in London, UK.
With the recent pandemic highlighting the need for rapid drug discovery, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning. The current challenges within the drug discovery industry include the significant time consumption and expenses involved. This conference will discuss the solutions to these problems with presentations and updates from leading industry experts.
AI in drug discovery is leading the way into a shorter, cheaper and more successful R&D era where compound generation is automated, drug synthesis is predictable and undruggable diseases are finally being targeted.
AI in drug discovery is becoming an integral part of the research and development area of treating diseases with more companies incorporating ‘Big Data’ and data scientists within their R&D teams. Although the AI in drug discovery area has grown rapidly over the past few years, those in the industry acknowledge that there is a long way to go. Collaboration and partnerships are the key to driving this area forward.
Join us at SMi’s 3rd annual AI in Drug Discovery conference and explore the latest industry updates in: the selection of targets using AI, decision making within drug discovery and closing the loop on AI in drug discovery. Don’t miss out on presentations from leaders within the field, giving insights into the latest industry advances and answering the big questions within AI in Drug Discovery.
Event Hashtag: #SMiAIDrugDis
Key Reasons to Attend:

Discover the main topics of research within industry, with talks on decision making, target selection and closing the loop
Engage with regulators about the guidance within machine learning and AI in Drug Discovery
Learn about the new breakthroughs within clinical trials and the treatment of disease
Explore the latest technologies in deep learning from leaders within the pharmaceutical industry
Discuss the impact of big data and how it applies to AI drug discovery within Pharma

Who Should Attend?
CEOs, Presidents, Vice Presidents and Global Heads, Executive Directors, Vice President & Global head, Principal Scientists, Heads of Business Development, Directors of Pharma/Biotech firms.

Transcription Factor-Directed Therapies Summit
2022-03-08 - 2022-03-10 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
The FDA’s recent approval of Welireg has sparked reinvigorated confidence in the field of Transcription Factor-therapeutics and as an increasing number of drug candidates are entering preclinical and clinical programs, this is a vital moment for the field.
For the first time, you can join leaders from BMS, Scorpion Therapeutics, Ikena Oncology, Kronos Bio and Talus Bio at the inaugural Transcription Factor-Directed Therapies Summit, the first in-person conference on precision molecular oncology uniting experts in proteomics, genomics, structural biology, and translational sciences.
Dedicated to overcoming specific drug development challenges of targeting this ubiquitous and highly complex system with novel TPD based modalities, this unique discussion forum will equip you with the knowledge to utilize Transcription Factors as biomarkers to better predict disease prognosis and progression.
Don’t miss your chance to join fellow pioneers of Transcription Factor medicine to overcome the critical roadblocks to success in small molecule inhibitors, PROTAC-based degraders, and other therapeutic approaches targeting STAT3, c-MYC, FOXP3, p53, MITF, NF-B, and many more Transcription Factors.
Ensure your Transcription Factor program reaches full clinical potential by gaining a better understanding of the underpinning biology of the transcription regulation network and how it relates to treating disease, whilst harnessing the novel discovery and screening technologies that are streamlining drug development and opening the field up to new therapeutics possibilities. Join us to seek out solutions to longstanding obstacles in transcription factor therapy development at all stages, from bench to bedside.
To know more visit: https://bit.ly/3pWWEj8

4th Chronic Kidney Disease Drug Development Summit
2022-03-01 - 2022-03-03 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
As SGLT2 inhibitors redefine standard of care, opportunities to establish efficacy with surrogate endpoints take a step forward, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting.
The 4th Chronic Kidney Disease Drug Development Summit is your only industry-led event dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders. Uniting 100+ industry heavyweights including AstraZeneca, Johnson & Johnson, Bayer, Boehringer Ingelheim, Novartis, Otsuka, Novo Nordisk, and many more, this is a conversation you cannot afford to miss.
From dissecting pivotal insight into implementing patient stratification to turn the tide on precision medicine, to the brand-new seminar dedicated to establishing a pathway to clinical success in AKI, this is the only end-to-end forum presenting scientific advancements as actionable insights.
We hope to see you in Boston this March to together discover opportunities to personalize organ-on-a-chip technology and explore advances in stem cell platforms to regenerate kidney tissue. Leave this meeting equipped to guide your strategic decisions for 2022 and implement evolving surrogate endpoints of eGFR slope, albuminuria, and real-world evidence into innovative trial design.
Take a look at the event guide here.

2nd Mitochondria-Targeted Drug Development Summit
2022-02-22 - 2022-02-24 | Hyatt Regency Boston / Cambridge, 575 Memorial Dr, Cambridge, MA, 02139, United States
We are happy to announce that the Mitochondria-Targeted Drug Development Summit, focused on the pursuit for novel effective therapies for mitochondrial disorders/dysfunction, will be delivered in-person, for its 2nd edition.
Mitobridge/Astellas, Minovia Therapeutics, Abliva, GenSight Biologics, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies.
To know more visit: https://mitochondria-targets.com/

Next Generation CAR-TCR Summit
2022-02-22 - 2022-02-24 | Novotel London West, 1 Shortlands, Hammersmith, London, W6 8DR, United Kingdom
As the CAR-T field continues to explode with new companies, investment, and clinical collaborations, it’s more important than ever to stay ahead of the curve. Stakeholders across oncology are now turning to next generation developments and innovations to create the therapies of tomorrow.
That’s why CAR-TCR Europe has evolved into the Next Generation CAR-TCR Summit: your definitive platform focused on the 2.0, next generation innovations in cell therapies.
Join you CAR-TCR community and network with 300+ innovators from large pharma, biotech, academia and regulatory boards at the only meeting dedicated to accelerating novel, new generation cell therapies that are safer, more effective and have meaningful impact in diseases beyond oncology.
You’ll hear insights into novel in-vivo delivery, innovations in gene, base & prime editing, novel discovery platforms, overcoming the hostile tumour microenvironment, improving persistence & durability for greater clinical outcomes, and more!
Key insights will be shared from Matterhorn Biosciences, Affini-T Therapeutics, Kiromic BioPharma, Antion Biosciences, Zelluna Immunotherapy, T-Kinfe Therapeutics, AffyImmune and many more. Leverage their knowledge to deliver value to your entire cell therapy team.
With 3 in-depth streams exploring the hottest Novel Platforms, Advanced Clinical Development of 3rd, 4th and 5th generation cell therapies, and the latest Manufacturing Innovations to revolutionise the production of large-scale cell therapy, this is the ONLY meeting bringing you the next generation developments and innovations needed to create the therapies of tomorrow.
Whether you are developing novel constructs, new clinical trial strategies or innovative manufacturing approaches for large scale production, this multi-tracked meeting can support your whole team and provide the tools needed to advance your own pipeline towards clinical and commercial success.
View official event guide now for the full meeting details!

3rd RAS/MAPK Pathway Targeted Drug Discovery Summit
2022-02-22 - 2022-02-24 | 8:30am – 5pm | Boston, MA In-Person and Digital Options Available
The Only Global RAS Dedicated Conference is Returning in 2022 with the 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit!
Year on year, we are proud to unite the leading frontiers of the RAS industry to showcase expertise, technical data and pipeline updates, all geared toward accelerating the discovery and development of anti-RAS therapies.
This February 2022, the summit returns to shine a spotlight onto pioneering discoveries and innovative strategies to target RAS, including a focus on success in targeting mutations beyond G12C and efforts to shut down the RAS/MAPK pathway at every turn.
As the industry springboards off the significant success of G12C covalent inhibitors against KRAS mutant cancers, leading experts are now shifting focus toward next-generation anti-RAS drugs, considering how we can leverage the RAS signaling pathway to treat all RAS mutant cancers, and overcome the critical escape mechanisms leading to treatment resistance.
To know more visit: https://ter.li/8ljo2k

LEAP HR: Life Sciences Europe
2022-02-21 - 2022-02-23 | The Pestana Amsterdam Riverside, Amsteldijk 67, Amsterdam, 1074 HZ, Netherlands
LEAP HR: Life Sciences Europe is your best opportunity to uncover the brand-new HR thinking that will enable you to tackle an ongoing talent shortage, and create the differentiated people strategies and organisational agendas you need to thrive in a hybrid life sciences operating environment.

Step inside 20+ case studies of how biopharma organisations of all sizes are thriving in new-hybrid working models – and leave with the inspiration you need to transform HR impact in your own organisation. Look beyond what’s previously not been possible and focus on how HR can transform its strategic impact in this fundamentally new working world that will enable your own organisation to compete more effectively for top life sciences talent.
Find out more > https://ter.li/tw2ss2

2nd Operationalize: Expanded Access Programs Summit
2022-02-15 - 2022-02-17 | Aloft Boston Seaport District, 401-403 D St, Boston, MA, 02210, United States
This 2nd Operationalize: Expanded Access Programs summit is here to bring you solutions.
By bringing together the world’s leading Expanded Access Programs thinkers, this exclusive platform will clarify the complex issues through end-to-end Managed Access/Compassionate Use program operationalization. Through open discussion, sharing best-practice case studies, and removing hypotheticals: this event provides an unrivaled opportunity to solve your challenges across the entire timeline.
Whether it’s program set-up, US and EU regulatory pathways, product supply, data collection, logistics, ethical considerations, or internal collaborating – ensure you aren’t repeating past mistakes by hearing global leaders recall their experiences with a shared goal of providing you with pragmatic solutions to solve these complex hurdles.
For more information visit: https://ter.li/f41rv0

4th Bacteriophage Therapy Summit
2022-02-14 - 2022-02-16 | Digital Event
From Translation to Market-Entry: Advance Formulation, Clinical Development, & Commercialization of Phage-Based Therapies at the 4th Bacteriophage Therapy Summit 2022.
Returning for its 4th year, the Bacteriophage Therapy Summit remains the only industry-focused forum dedicated to facilitating the discovery, translation & acceleration of bacteriophage research into targeted therapeutics with clinically significant results. View the full event guide here: https://ter.li/ehl7e1
2022 Agenda Overview:

Navigate clinical trial rationale, distribution effects of formulation on reaching infection sites, lessons learned from compassionate use trials, and the regulatory pathway for commercial development with the hottest insights from our 35+ expert speaker faculty
Hear from international organizations including the FDA, BiomX, Locus Bioscience, Felix Bioscience, Phagomed, PhagePro, Cytophage, Sciphage and unite with the phage community prioritizing human health and diseas
Discuss strategies to weaponize phage therapies including lysins, genetic engineered and combination approaches to create new pathways for the treatment of infectious diseases, across 3 days of unparalleled, industry-centered content
Keep your company’s interest in bacteriophage therapies up-to-date and aligned with the new breakthroughs beyond basic science and establish your pathway to commercialization in 2022 and beyond

See our full speaker faculty, all agenda topics, and our attending audience in our event brochure: https://ter.li/ehl7e1
Join us to develop the next generation of phage therapy products disrupting the medical and healthcare industries for a better tomorrow. Early booking and group discounts are available upon request. Please visit the website for more information on registration fees and discounts. https://ter.li/1szl1y

SMi’s 5th Annual 3D Cell Culture Conference
2022-02-09 - 2022-02-10 | Virtual Conference: Online Access Only
SMi’s 5th Annual 3D Cell Culture Conference
Virtual Conference: Online Access Only
9-10 February 2022
http://www.3d-cellculture.com/
Sponsored by: CELLINK, CelVivo, Promega and Newcells BiotechDeveloping Complex, Translatable and Physiologically-Relevant Cellular Models in vitro
Conference Co-Chairs: Stefan Przyborski, Professor of Cell Technology, Durham University and Philip Hewitt, Global Head of Early Investigative Toxicology, Merck
3D Cell Culture is gaining momentum in the pharmaceutical industry on account of the advantages such models pose for in drug discovery, from improved clinical translation and predictivity, to patient safety and sustainability.
SMi’s 3D Cell Culture Conference will explore advances in the application of 3D cell models, from their employment in drug screening to reduce candidate attrition, to the latest insights into microphysiological systems, the regulatory landscape, and the clinical applications of 3D bioprinting.
Event Hashtag: #SMi3DCellCulture
Key Benefits of Attending:

Discuss the uses of advanced cell technologies to construct in vitro models of human tissues
Explore the regulatory sciences surrounding Microphysiological systems, and their development and adoption for drug safety assessment
Uncover the major benefits of 3D modelling in enhancing clinical translation and predictability
Utilise 3D cell culture for High Throughput drug discovery and Content screening over traditional 2D methods

• Delve into advanced case studies looking into organ models: from organotypic lungs to liver spheroids

WHO SHOULD ATTEND?
Biotech / Pharma Companies – Team Leader, Junior Principle investigator, Cell and Molecular Scientist, Chief Scientific Officer, Deputy Director, Manager, Founder, CEO, Head, Director, Programme Manager, Lab Head, Toxicologist
Academia Professor – Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering
Solution Providers – Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director, Vice President, COO
Organisations / Regulatory – Director, Senior Science Advisor, Scientific Officer

SMi’s 13th Annual RNA Therapeutics Conference
2022-02-09 - 2022-02-10 | Virtual Conference: Online Access Only
SMi Group’s 13th Annual Conference:
RNA Therapeutics 2022
9th – 10th February 2022
Virtual Conference: Online Access Only
www.therapeutics-rna.com
Sponsored by: BIA Separations | eTheRNA Immunotherapies | Thermo Fisher Scientific
Bolstering the latest advances and opportunities in RNA-based medicine
The RNA therapeutics industry has grown at an exponential rate in recent years, with an increased spotlight following the industry’s leading role in developing vaccines against COVID-19 in response to the global pandemic. This year’s conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development.
The 2022 agenda will explore innovations in novel and targeted delivery, RNAi innovations and antisense oligonucleotide therapeutics. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of RNA with case studies on the treatment of cardiovascular disease, neurological diseases, and oncology.

5th Antigen-Specific Immune Tolerance Summit
2022-01-26 - 2022-01-27 | Digital Event
Returning for its fifth year, the Antigen-Specific Immune Tolerance Summit will lean into the industry’s key challenges of understanding the mechanisms inducing tolerance, characterizing driver antigens of disease, monitoring immune response, and accelerating durable therapies into the clinic.
This is your comprehensive guide to define your drug development strategy for 2022 and delve into the therapeutic opportunity held by the next generation of antigen-specific immunotherapies. Expect to be involved in interactive discussions on:

Examining the mechanisms underlying immune tolerance to drive antigen and epitope discovery with insights from the NIH, Vaccibody, and Imcyse
Leveraging immune biomarkers and explore immune tolerance in diabetes with Novo Nordisk, COUR Pharmaceuticals, and Diamyd Medical
Exploring the diversity of technologies and platforms for antigen delivery withToleranzia, Idogen AB, and AnTolRx, Inc
Optimizing clinical durability and efficacy of antigen-specific immunotherapies with insights from WORG Pharmaceuticals, and Cellerys

Uniting 80+ industry experts to discuss cutting-edge content exploring the latest advances in the field of antigen-specific immune tolerance, this is a conversation not to miss.
Take a look at the event guide here.

mRNA- Based Therapeutics Summit Europe
2022-01-25 - 2022-01-27 | Digital Event – CET
Built with biopharmaceutical industry insights, this conference will bring together key opinion leaders from Europe and the rest of the world to delve deep into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines & therapeutics with improved specificity, delivery & efficacy for immuno-oncology, infectious diseases and beyond.
With 20+ pioneering large pharma, biotech and academic experts who are shaping the landscape of mRNA- based therapeutics for the scientific community world-wide, hear how they address the major challenges facing the industry.
Key Highlights:

Optimise the Efficacy, Cell- & Tissue- Specificity & Translatability of Your mRNA- Based Pipeline

With the limitless opportunity of mRNA- based Therapeutics across different modalities, consider the challenges of efficacy and improve cell- & tissue- specificity with expert insights from Professor Drew Weissman, Strand Therapeutics & Chalmers University of Technology

Explore Applications of mRNA- Based Therapeutics Beyond Infectious Diseases

From immune-oncology to rare and autoimmune diseases, dive into emerging applications and potential challenges of mRNA- based vaccines and therapeutics beyond infectious diseases with case studies from Moderna, BioNTech & Ethris

Navigate New & Emerging Delivery Technologies for mRNA- Based Therapeutics

Take yourself to the forefront of mRNA delivery system development, from structure through to administration with insights from BioNTech, Johnson & Johnson & 20Med Therapeutics

Strategise Your Scalable & Global mRNA-Based Vaccine Development

With the global outreach of mRNA- based vaccines, scalability is a major hurdle. Hear the latest technological advances and regulatory standards in mRNA- based vaccine and therapeutic landscape from Sanofi, Ziphius Vaccines & Arcturus Therapeutics

Tune into How Companies are Differentiating Their Pipelines Beyond mRNA- Based Vaccines

With the success of mRNA- based vaccines fulfilling novel technologies and therapies such as mRNA- based protein replacement, hear from companies like Strand Therapeutics, Turn Biotechnologies & Orna Therapeutics on the emerging strategies that will enable innovation in the field
To know more visit: https://ter.li/og1teo

DDR, ATR & PARP Inhibitors Summit
2022-01-25 - 2022-01-27 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
The 5th Annual PARP, ATR & DDR Inhibitors Summit is the one-of-a-kind industry-focused summit dedicated to bringing new and novel next-generation DDR therapeutics to the clinic and finding optimal treatment combinations to expand application in multiple cancer indications.
This is the key in-person biopharma conference for any research team developing inhibitors of specific DDR targets, in either monotherapy or in combination, to treat predictable, identifiable, DDR-defective cancer indications.
If you are a research team striving to create best-in-class DDR therapeutics, this is the specific networking forum that has been curated with you in mind.
What Will We Cover?

Delve into the progress in PARP, ATR & Wee1 including biomarker understanding with AstraZeneca, Bayer, Repare, Merck KGaA, Atrin Pharma, IMPACT Therapeutics, Onxeo, FoRx & Zentalis

Optimize pre-clinical development through models, novel methodologies & imaging technologies to revolutionize translation with NCI, XPose Therapeutics, Dana-Farber Cancer Institute & Harvard

Uncover the therapeutic potential & progress in targeting Polθ, WRN, CHK1, DNA-PK, USP1, PARG, PKMYT1 with Artios Pharma, Harvard, NERx Bio, KSQ Therapeutics, IDEAYA & Repare Therapeutics

Discover the clinical updates on combination, dosing, scheduling & future directions for this exploding field with Newcastle University, MD Anderson, National Brain Tumor Society, Yale, Breakpoint Therapeutics & Harvard

Network In Person with your peers, ask your burning questions, build connections, and fully immerse yourself in the world of DDR therapeutics.

A Virtual Attendance Option, giving you access to the same premium quality content as the in-person event, dedicated virtual networking opportunities, & the ability to engage with our event partners

To know more visit: https://ter.li/uzjvgi

TGF-β for Immuno-Oncology Drug Development Summit
2022-01-25 - 2022-01-27 | Virtual Event
It is clear the world of TGF-β contains vast potential and excitement, in the past year alone we have seen great advances, clinical setbacks, and novel insights into the role of TGF-β.
Over the last 12 months, we have seen so many highs and lows, including clinical updates from large pharma such as Novartis, Oncotelic Therapeutics, Sanofi. It is also exciting to see emerging biotechs progressing in this area – from Transcenta’s clearance with the FDA for Ph1 anti-PD-L1/TGFb antibody to Lassen Therapeutics uncloaking $31m for their candidate.
With the vast volume of candidates moving into the clinic, it is vital for this community to reconnect at the 2nd TGF-β for Immuno-Oncology Drug Development Summit, the definitive industry-led meeting to harness the therapeutic potential of this target and supercharge pipeline progression.
Tailored with 31+ senior leaders, the 2022 meeting will return with a fresh speaker line-up and dedicated 2 tracks content for a comprehensive guide on TGF-β in immuno-oncology. Whether you are new to this field or a seasoned expert, this meeting will provide you with the must-know takeaways from biology to translational modeling, from biomarkers to clinical trial design across 3 days.
What’s New?

31+ world-class speakers from Scholar Rock, Novartis, Pfizer, Mestag Therapeutics, Takeda, Cue Bio, Genentech, and more
2 Dedicated Tracks of exclusive preclinical and clinical case studies and data for your invaluable lessons learned
A TGF-β Boot Camp Day to provide a comprehensive guide on harnessing the potential of this complex target

To know more visit: https://ter.li/nep8yi

HFpEF Drug Discovery & Development Summit 2022
2022-01-25 - 2022-01-27 | Omni Parker House, 60 School St, Boston, MA, 02108, United States
Heart failure affects about 6.2 million people in the United States, with half of the patients having heart failure with preserved ejection fraction (HFpEF) and counting. Yet, there is no treatment for this form of the disease as HFpEF is a heterogeneous syndrome and, like other disease areas, this makes it difficult to develop effective therapeutics that will work for patients in each of the subtypes.
The HFpEF Drug Discovery & Development Summit 2022 is the first industry-specific forum exclusively focused on showcasing the latest drug development and translational research in HFpEF and its relationship with metabolic syndromes and co-morbidities, whilst giving you the pivotal insights you need to kickstart the next generation of clinically defining therapeutics for HFpEF to avoid late-stage clinical trial failures.
With 20+ hours of content, an interactive workshop, and over 5 hours of networking with key industry leaders from Amgen, Cardiobiopharma, AstraZeneca, NeoProgen, Eli Lilly, Bayer, Novartis, and more, this comprehensive forum will completely focus on innovative research and state of the art science in HFpEF and the current challenges and opportunities in the field.
Make this your 2022 must-attend meeting and network with 80+ senior CSOs, CEOs, research scientists, and academics committed to tackling this form of heart failure and provide a meaningful impact on the lives of over 3.1 million patients suffering from HFpEF worldwide.
Take a look at the full event guide here.

6th Microbiome Movement - Drug Development Summit Europe
2022-01-25 - 2022-01-27 | The Tower Hotel, St. Katharine's Way, London, E1W 1LD, United Kingdom
Decipher Mechanisms of Action, Understand Clinical Data & Ignite Partnership Opportunities to Accelerate Your Microbiome Research

Whilst emerging phase 3 data is set to ignite investment and uncover the reality of microbiome-based therapeutics, there remain analytical challenges and translational bottlenecks that the community must come together to overcome, to redefine biopharmaceutical treatment and diagnostic options.
The community is now closer than ever to obtaining an available, approved and commercial microbiome-based therapeutic. This conference joins scientists, clinicians, entrepreneurs and academics, to help assist this success. Persistent hurdles and ongoing challenges with microbiome drug development mean that real-life discussions and learnings are imperative to moving this exciting field forward.
From understanding the microbiome functionality, leveraging lessons from pre-clinical and clinical development, scaling manufacturing processes and regulation hurdles, our discussion will leave you with a holistic view of the European end-to-end development of microbiome therapeutics.
The Microbiome Movement provides the perfect opportunity to actualise the therapeutic promise that the microbiome has provided, by bringing these challenges to the forefront and tackling them head on over three days of extensive content. With the sharing overall aim to commercialise a microbiome-based product.
To know more visit: https://ter.li/rk0suq

SMi’s Transdermal and Microneedle Delivery
2022-01-24 - 2022-01-25 | Virtual Conference: Online Access Only
SMi’sTransdermal and Microneedle Delivery
24-25 January 2022
Workshop: 26th January 2022
Virtual Conference: Online Access Only
www.transdermal-microneedle-delivery.co.uk/PharmajournalistWL
#SMiTransdermal
Sponsored by: LTS Lohmann Therapie-Systeme AG and QuadMedicine
Co-Chaired by:
Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University
Tycho Speaker, Director, Drug Delivery and Biomaterials, AbbVie Ltd
SMi’s inaugural conference: Transdermal and Microneedle delivery will take place on 24th – 25th January 2022
SMi is proud to present the Transdermal and Microneedle Drug Delivery Conference, taking place on the 24th to 25th January 2022, Virtual Conference: Online Access Only. Transdermal and Microneedle Drug Delivery Conference will explore real world applications of microneedles in drug delivery and strategies for device design while engaging in the latest innovations in device design and formulation with case studies from thought leaders.
The conference will consider key developments in the transdermal drug delivery field, including the innovations in microneedle technology for a COVID-19 vaccine and opportunities for development in cancer vaccine delivery, advances in microarray patches, and microneedle-based diagnostics. Key regulatory updates including guidance on classification of microneedle devices and considerations for ensuring quality will be presented by regulatory experts for a comprehensive outlook of this exciting and ever-growing field, and the importance of considering human factors in order to enhance the user experience will be presented by industry experts.
This two-day agenda offers you peer-to-peer networking with leaders in transdermal and microneedle delivery. We look forward to welcoming you to the conference in January.
Key Reasons to Attend:

Gain insight into developments in microneedles for drug delivery and diagnostics
Hear key regulatory updates from regulatory bodies including FDA and WHO on guidance for regulatory compliance
Explore new applications of microneedle technology in vaccinations
Discover advances in design and application of transdermal patches
Explore and benchmark against industry developments through case studies and real world examples in device development for microneedles

Download the brochure at: www.transdermal-microneedle-delivery.co.uk/PharmajournalistWL
Who Should Attend?

Drug-Delivery Device Developers
Microneedle Device Developers
Transdermal Delivery Developers
Microarray Patch Developers
Medical Device Engineers
Primary Packaging Material DesignersSecondary Packagers
Smart Device Developers
Training Device Developers
Device-Safety Solution Providers
Drug Developers
Transdermal Drug Product Developers

3rd Glioblastoma Drug Development Summit
2022-01-18 - 2022-01-20 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
The 3rd Glioblastoma Drug Development Summit is the only industry led forum for large pharma, biotech and academic KOLs to unite under the common goal of accelerating the practical translation and clinical development of meaningful therapies for the treatment of glioblastoma.
Through investigating the clinical implementation of diverse mechanisms of action, including, DNA damage repair, immunotherapy, oncolytic viruses, cholesterol metabolism, PARP inhibitors and more, we strive to address the urgent need for novel and much improved treatments for this devastating disease.
Tackling specific drug development challenges such as a better understanding of preclinical efficacy and tolerability data to confidently translate into the clinic, improving drug delivery across the blood-brain barrier and optimizing clinical trial design to define more measurable outcomes, this meeting is an absolute must attend for all neuro-oncologists and oncology professionals determined to translate their drug candidates into human clinical trials.
With a huge unmet medical need for effective treatments and too many clinical failures to overcome, there has never been a more important time to attend the 3rd Glioblastoma Drug Development Summit and join your dedicated and determined community to defeat GBM and radically change patients’ lives.
Join us as we unite drug developers and academics to tackle unique drug development challenges creating obstacles for effective treatments for GBM patients.
To know more visit: https://ter.li/2bmg9q

SMi’s 10th Annual Pharmaceutical Microbiology UK Conference
2022-01-17 - 2022-01-18 | London, UK
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference
Conference: 17 – 18 January 2022
Workshops: 19 January 2022
Location: Virtual Conference: Online Access Only
Website: http://www.pharma-microbiology.com/PJwl
Sponsored by: CTL-MAT, Ecolab and Microgenetics
Chaired by: Di Morris, Clinical Auditor, AstraZeneca
Exploring Robust Risk-Based Microbiological Control Strategy
SMi’s flagship microbiology conference is celebrating its 10 year anniversary. The conference taking place on 17 and 18 January 2021 in London, UK will bring together microbiology industry experts.
Microbiology remains an essential tool for the detection of microorganisms present in biopharmaceutical and pharmaceutical batches. The two-day conference will explore the most pressing topics in this thriving field, from the movement toward process automation and minimisation of operator intervention, to the latest technologies in rapid microbiological testing methods and data integrity.
#SMiPharmaMicroUK
Key Reasons to Attend:

Discover case studies in establishing holistic Contamination Control Strategies and Real-Time Viable Air Particle Counting with leaders in the pharmaceutical industry
Gain insight the current state of Endotoxin testing, including alternative test methods and strategic approaches to method validation
Explore the best practice in data integrity and the automation of environmental monitoring in the Microbiology Quality Control Lab
Join the important panel discussion on diversity and inclusion in the workplace with an experienced line-up of speakers
Discuss the latest developments in the detailed, rapid detection of microbes in pharmaceutical water

Download the brochure at: http://www.pharma-microbiology.com/PJwl
Who Should Attend?
Senior Microbiologist, Lead Scientist, Laboratory Manager, QA Specialist Drug Substance External Manufacturer, Business Development Manager – Testing, Pharmaceutical Microbiology Consultant, Higher Pharmacopoeia Scientist, Analytical Standards Specialist

SMi's Pre-Filled Syringes and Injectable Drug Devices
2022-01-12 - 2022-01-13 | Virtual Conference: Online Access Only
SMi’s Pre-Filled Syringes and Injectable Drug Devices
12th January to 13th January 2022,
Virtual Conference: Online Access Only
Conference: 12 – 13 January 2022
Focus Day: 11 January 2022
Location: Virtual Conference: Online Access Only
Website: http://pre-filled-syringes.com/pharmajournalist/WL
Sponsored by: BD Medical – Pharmaceutical Systems, Crux, Nemera, Zeon Europe GmbH
Chaired by:
Bjørg Kaae Hunter, Department Manager, RA CMC & Device; RA NextGen Drug-Device, Novo Nordisk and Daniel Latham, Head Connected Health Product Development, Novartis
The Future of Drug Delivery and Combination Product Device Design
The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products. This year’s conference will explore the exciting advances in the combination product delivery space including insights into how the industry is adapting to the delayed EU MDR, takeaways from the global pandemic and a future outlook exploring how pharma, device developers and regulators can work together to encourage innovation. Part of the leading injectables series of events, SMi’s 14th annual conference will bring you the key insights you need to grow and enhance your pre-filled syringes portfolio and discover what the future holds for the PFS and combination products industry.
#PFSSMi
Key Reasons to Attend:

Engage with industry leaders on the key takeaways from the pandemic and how this can be applied to future accelerated development
Explore updates to drug device combination product design approaches putting the user first with industry case studies from big pharma
Assess the current landscape of device delivery mechanisms and how industry can work together to promote innovation
Understand the landscape of delivery for novel drug products, fragile molecules and long acting injectables in the interactive panel discussion

Download the brochure at: http://pre-filled-syringes.com/pharmajournalist/WL
Who Should Attend?
Drug-delivery developers, Medical Device Engineers, Primary Packaging material designers, Secondary packagers, Smart device developers, Training device developers, Device-safety solution providers, Drug developers
